G17DT
Sponsors
Cancer Advances Inc.
Conditions
Colorectal CancerGastric CancerJaundicePancreatic Cancer
Phase 2
Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.
CompletedNCT02098239
Start: 1999-08-31End: 2002-05-31Updated: 2014-03-27
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
CompletedNCT02098291
Start: 1999-04-30End: 2002-02-28Updated: 2014-03-28
Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.
CompletedNCT02181465
Start: 1993-10-31End: 1994-05-31Updated: 2014-07-04
Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.
CompletedNCT02223078
Start: 2000-07-31End: 2001-11-30Updated: 2017-06-20
A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer
TerminatedNCT02228785
Start: 1994-05-31Updated: 2014-08-29
Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.
CompletedNCT02233712
Start: 1999-08-31Updated: 2014-09-08
Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer
CompletedNCT02450032
Start: 2000-02-29End: 2001-05-31Updated: 2015-05-21
Effect of G17DT in Patients With Stage II/III Colorectal Cancer
CompletedNCT02518373
Start: 2000-04-30End: 2001-02-28Updated: 2015-08-07
Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
CompletedNCT02518529
Start: 2001-02-28End: 2002-12-31Updated: 2015-08-10
Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
CompletedNCT02521649
Start: 1998-09-30End: 2001-01-31Updated: 2015-08-13